A sphingosine-1-phosphate type 1 receptor agonist inhibits the early T-cell transient following renal ischemia–reperfusion injury  by Lai, L.-W. et al.
see commentary on page 1193
A sphingosine-1-phosphate type 1 receptor agonist
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T cells are thought to be involved in the pathogenesis of
renal ischemia–reperfusion injury (IRI); however, earlier
studies have not found significant T-cell numbers in the
kidney following injury. In this study we test the hypothesis
that T cells transiently infiltrate the kidney following
reperfusion and leave behind T-cell-derived cytokines such as
interferons and interleukins, thus triggering an inflammatory
reaction. An early rise of infiltrating T cells was coupled with
a decrease in both circulating lymphocytes and CD4þ cells
of periarterial lymphocyte aggregates. The renal expression
of several chemokines was rapidly and markedly increased by
ischemia–reperfusion (IR). Sphingosine-1-phosphate type 1
receptor agonists have been shown to protect kidneys from
injury. One of these agonists given before IR significantly
reduced histologically assessed renal injury, circulating
lymphocyte numbers, and renal T-cell infiltration. This
pretreatment did not, however, affect the increase in T-cell
chemokines but caused an increase in CD4þ cells in the
renal lymphatic system. We conclude that T-cell infiltration is
an early event after IRI and is mediated by several
chemokines. Sphingosine-1-phosphate receptor agonists
reduce renal injury and T-cell infiltration in spite of
chemokine generation by inhibiting T-cell mobilization from
both renal and extra-renal lymphoid tissue.
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The pathogenetic mechanisms of ischemic renal injury
involve multiple signal transduction cascade systems that
lead to tubular injury, endothelial dysfunction, and inflam-
mation.1,2 T cells have been implicated in the pathogenesis of
ischemia/reperfusion (IR) injury (IRI) in the kidney.3–6 Using
T cell-deficient mice and adoptive transfer of T cells, Rabb
and coworkers concluded that T-cell modulation of kidney
IRI is largely independent of neutrophil infiltration into
kidney.7,8 Many chemokines have been shown to recruit T
cells to sites of inflammation, including CC chemokines such
as monocyte chemoattractant protein 1 (MCP1 or CCL2),
regulated upon activation normal T cell expressed and
secreted (RANTES or CCL5), macrophage inflammatory
protein 1a (MIP1a or CCL3) and macrophage inflammatory
protein 1b (MIP1b or CCL4), and CXC chemokines such as
monokine-induced by interferon-g (MIG or CXCL9), inter-
feron-inducible protein of 10 kDa (CXCL10), and interferon-
inducible T-cella (I-TAC, CXCL11).9–11 Among them,
monocyte chemoattractant protein 1, interferon-inducible
protein of 10 kDa, and RANTES have been demonstrated in
the kidney after IRI.12–15 However, previous studies failed to
demonstrate significant T-cell infiltration after IRI in the
kidney. A ‘hit-and-run’ hypothesis has been proposed,
suggesting that T cells may infiltrate the kidney in the early
phase of IRI and exit the scene rapidly, leaving behind
multiple T-cell-derived cytokines such as interferon-g,
interleukin-4 (IL-4), and IL-2, which trigger the inflamma-
tory reaction in the kidney.4
Recently, a new class of immunosuppressive agents has
been developed based on a unique action of blocking T-cell
egress from lymph nodes and other lymphoid tissues via the
G-protein coupled receptor, sphingosine-1-phosphate 1
(S1P1) receptor.
16 FTY720, the first of such agents, is a
non-selective S1P receptor agonist, whose activation requires
phosphorylation.17 More recently, SEW2871 has been
identified as an S1P1-selective agonist and it activates the
receptor without phosphorylation.18,19 Both FTY720 and
SEW2871 have been shown to protect the kidney against
IRI.20–22 We reported recently that SEW2871 ameliorates
renal IRI in mice by preserving renal function, reducing
neutrophil and macrophage infiltrates, and severity of acute
tubular necrosis. These findings are associated with a
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significant reduction in gene expression of proinflammatory
cytokines and adhesion molecules. Although we clearly
demonstrated lymphocytopenia in the animals pretreated
with SEW2871, similar to other investigators, we did not
detect any significant T-cell infiltrates 24 h after IRI.21
In this study, we set out to analyze T-cell infiltrates at
earlier time points of IRI by immunofluorescence (IF)
staining and to evaluate the effects of S1P1-selective agonism
on renal IRI and T-cell infiltration. Our studies provide
important evidence that T-cell infiltration occurs very early
after IRI, probably through chemokine effects, and these T
cells may come from both circulation and renal lymphatic
systems. The S1P1-selective agonist can overcome the
chemokine effects and prevent T-cell infiltration by inhibiting
T-cell egress from both local and distant lymphoid tissues.
RESULTS
T-cell infiltration is an early and transient event in the
acute phase of renal IRI
To examine T-cell infiltration, we performed IF staining on
renal cryosections using anti-CD4 antibodies. Because S1P1
receptor is important for T-cell trafficking,23,24 we carried out
dual staining to determine whether CD4þ cells express S1P1
receptors. In the control kidney, there were few CD4þ T
cells (Figure 1b, upper panel, stained red), whereas 1 h after
reperfusion, several CD4þ cells were found in the
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Figure 1 | Early T cell infiltration following renal ischemia and reperfusion (IR) injury is inhibited by SEW2871. Dual IF was performed
by using anti-CD4 (red) and anti-S1P1 (green) antibodies, respectively (original magnification  1000). Few CD4þ T cells are seen in
non-ischemic control (ctrl) kidney (b, upper panel). T cells increased at 1 h after IR injury (b, middle panel) and pretreatment with SEW2871
(SEW) reduced T cells (b, lower panel). All CD4þ T cells are positive for S1P1 receptor. To demonstrate that CD4þ cells are present in the
interstitial space and outside of peritubular capillaries, the boundary of renal tubules is outlined in a (left, same as b middle panel, and right,
same as b, lower panel).
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interstitium (Figure 1b, middle panel). These CD4þ cells
were outside of tubules and not surrounded by endothelial
cells, which were positive for S1P1 receptor and negative for
CD4 (Figure 1a, where tubules and interstitial space were
outlined). These infiltrating lymphocytes in post-ischemic
kidneys were also demonstrated by the H & E section (Figure
2a). All CD4þ cells expressed S1P1 receptors (Figure 1b,
stained green) and IRI did not affect the intensity of S1P1
staining. Similarly, T-cell infiltration was also observed 4 h
after reperfusion, but very few T cells were found at 24 h.
To quantify the T-cell infiltration, the entire cross-section
of renal parenchyma was scored for CD4þ cells, and
expressed as CD4þ cells/mm2. For each kidney section,
80–100 high-power fields ( 400) were examined in a
blinded fashion. The CD4þ cells found in the periarterial
space, as described in the next section, were not counted as
infiltrating T cells. There were 2.570.3 CD4þ cells/mm2 in
the normal kidneys. Renal IRI induced 2.5-folds increase in
T-cell infiltrate in the kidney 1 h after reperfusion, which
remained elevated at 4 h (both Po0.05), then reduced to
baseline at 24 h (Figure 2b, upper panel).
T cell aggregates in the periarterial area along the pelvic
fornix
While examining kidney sections for T cells, we observed
clusters of CD4þ T cells (20–40 cells) in the periarterial area
between renal cortex and the lining of the renal pelvis along
the pelvic fornix (Figure 3a, upper panel). H- & E-stained
sections (Figure 3b) in both low- ( 40, left panel) and high-
( 400, right panel) power views further demonstrate the
location of the T-cell aggregates (Figure 3b, arrows in right
panel). After IRI, while the infiltrating CD4þ cells in the
interstitium increased, the CD4þ cells in the lymphocyte
aggregate reduced significantly (Figure 3a, middle panel).
Renal IRI is associated with significant lymphocytopenia
To evaluate whether circulating lymphocytes may be a source
of infiltrating T cells in the kidney after IRI, total peripheral
blood counts with differentiation were performed. We found
that IRI significantly reduced circulating lymphocytes. The
lymphocyte count was reduced by 64% at 1 h, and 56% at 4
and 24 h after reperfusion (Figure 2b, lower panel, all Po0.05).
Expression of T-cell-related chemokines after IRI
As mentioned earlier, CCL2, CCL5, and CXCL10 have been
shown to increase after IRI in the kidney; however, most
studies were performed at least 3 h after reperfusion.12–15 To
determine whether these chemokines are upregulated to
account for the early infiltration of T cells, we measured their
mRNA abundance using real-time reverse transcription-
polymerase chain reaction in the kidney at 1 and 4 h after
reperfusion. IRI significantly increased mRNA abundance of
CCL2, CCL5, and CXCL10 at 1 h after reperfusion. At 4 h,
CCL2 continued to rise, whereas CCL5 and CXCL10 became
lower, but still significantly higher than the baseline
(Figure 4).
S1P1-selective agonism reduces renal T-cell infiltration and
circulating lymphocytes
SEW2817 have been shown to cause lymphocytopenia by
blocking the lymphocyte egress from lymphoid tissues.18 We
pretreated mice with SEW2871 (20 mg/kg body weight) 3 h
before renal ischemia and examined CD4þ cells in kidneys
1–24 h after reperfusion. With SEW2871 pretreatment, there
were very few CD4þ cells in the interstitium at 1 (Figure 1b,
lower panel, stained red), 4, and 24 h after IR. The results of
CD4þ cell count revealed that T cell number was reduced
both at 1 and 4 h (35 and 43% reduction, Po0.05) after
reperfusion vs respective IR group (Figure 2b, upper panel).
Furthermore, the reduction of T-cell infiltration was
associated with severe lymphocytopenia at 1 and 4 h after
reperfusion, representing a reduction of 75–77%, compared
with the IR group alone (Figure 2b, lower panel). SEW2871
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Figure 2 | Renal ischemia and reperfusion (IR) injury causes early
T cell infiltration and lymphocytopenia. In the control kidney
(a, left panel, H&E stain, original magnification  400), very few
lymphocytes are seen, while 1 h after IRI, there are several
lymphocytes (arrows) in the interstitial space (a, right panel). Renal
infiltrating CD4þ T cell counts (b, upper panel) are transiently
increased after renal IR injury, which are associated with a decrease in
peripheral blood lymphocyte counts (b, lower panel). SEW2871 (SEW)
pre-treatment significantly reduces T cell infiltration and peripheral
blood lymphocyte counts when compared with IR only. N¼ 4–6.
*Po0.05 vs baseline; #Po0.05 vs IR.
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treatment without IR also induced a similar reduction in
peripheral lymphocyte count (data not shown). It has been
shown that the reduction of circulating lymphocytes by S1P1-
selective agonism is due to the inhibition of lymphocyte
egress from the secondary lymphoid tissues,18 and our data
suggest that SEW2871 treatment may contribute to the
reduction of T-cell infiltration in the kidney via similar
mechanisms.
S1P1-selective agonism induces log-jammed CD4þ cells in
renal periarterial lymphatic system
Interestingly, although the SEW2871 treatment significantly
reduced the infiltrating CD4þ T cells in the interstitium, it
markedly increased the CD4þ T cells in the T-cell aggregate
in the periarterial area. The CD4þ cells were heavily packed
and log-jammed against the endothelium of lymphatic vessel
(Figure 3a, right-lower panel, arrow indicates endothelium).
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Figure 3 | Demonstration of T cells in periarterial lymphoid cell aggregates by (a) dual IF (anti-CD4 (red) and anti-S1P1 (green)
antibodies, original magnification  1000) and (b) H & E staining. About 50% of cells in the aggregate are CD4þ cells in the non-ischemic
control (ctrl) kidney (a, upper panel). These aggregates (rectangles in b, left panel, original magnification  100) are located in the periarterial
area between renal cortex and the lining of the renal pelvis. The right panel shows the magnified ( 400) rectangle area with T-cell
aggregates (arrows). Fewer CD4þ cells were seen 1 h after IRI (a, middle panel). Pretreatment with SEW2871 increased CD4þ cells in the
aggregate and the T cells appear ‘log-jammed’ against the endothelium of a lymphatic vessel (arrows in a, lower right panel and in b, lower
right panel). All CD4þ T cells were positive for S1P1 receptor.
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To demonstrate further the location of the jammed T cells,
the H- & E-stained section in both low- ( 40, left panel)
and high- ( 400, right panel) power views are shown in
Figure 3b (arrows in right panel). Similar increase of CD4þ
cells in the periarterial lymphatic system was observed in
mice receiving SEW2871 treatment without IRI (data not
shown). This finding suggests that the reduction of T-cell
infiltration by S1P1-selective agonism is at least partially
caused by the inhibition of T-cell egress from lymphocyte
aggregates in the renal lymphatic system.
S1P1-selective agonism does not affect the upregulation
of T-cell chemokines by IRI
Since CCL2, CCL5, and CXCL10 are produced by endothelial
cells25 and S1P1 receptors are abundant in endothelial cells,
26
we investigated whether SEW2871 has any effects on the
upregulation of T-cell chemokines by IRI. Our results show
that compared with IRI alone, SEW2871 significantly
increased CXCL10 mRNA abundance at both 1 and 4 h,
but did not affect CCL2 or CCL5 (Figure 4). These data
suggest that the inhibition of lymphocyte egress by S1P1
agonism can overcome the chemotactic effects of the potent
T-cell chemokines, such as CCL2, CCL5, and CXCL10.
S1P1-selective agonism ameliorate early IRI in the kidney
We examined renal histopathology to assess the degree of
damage by IRI at 1 and 4 h after reperfusion and the effects of
SEW2871 pretreatment on renal damage. SEW2871 treat-
ment alone did not cause any visible damage (Figure 5, upper
right panel). With 1-h reperfusion, there were vacuolation
and desquamation in some tubules, particularly in the
cortico–medullary junction (Figure 5, middle left panel). At
4 h, we observed loss of tubular epithelial cells, cast
formation, and severe congestion (Figure 5 lower left panel).
Pretreatment of SEW2871 reduced IR-induced tubular
damage at both 1 (Figure 5, middle right panel) and 4 h
(Figure 5, lower right panel), and diminished congestion at
4 h (Figure 5, lower right panel). Very few neutrophils were
seen in either group at 1 or 4 h. The acute tubular necrosis
scores at 1 and 4 h were reduced significantly by SEW2871
treatment (Figure 6). As for renal function, SEW2871
treatment significantly lowered levels of plasma creatinine
and blood urea nitrogen (BUN) at 4 h after reperfusion, when
compared with IRI group alone (both Po0.05). The
functional amelioration continued at 24 h (Figure 7).
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Figure 4 | Relative renal mRNA abundance of CCL2, CCL5, and
CXCL10 with IRI (solid line) and IR and SEW2871 (SEW) treatment
(dashed line). mRNA abundance is normalized with dynactin mRNA
and expressed as folds of the baseline level. All values at 1 and 4 h
are significantly higher than the baseline values. N¼ 6–8.
*Po0.05 vs baseline; #Po0.05 vs IR.
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Figure 5 | Histology examination of the kidney (H & E stain,
original magnification  400). SEW2871 alone did not cause any
damage (upper right). There was early tubular damage at 1 h after
reperfusion (middle left). Loss of epithelial cells, cast formation,
and severe congestion are observed 4 h (lower left), SEW2871
treatment reduced tubular damage at 1 h (middle right), and 4 h
(lower right) significantly.
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DISCUSSION
Our study has demonstrated for the first time that T-cell
infiltration indeed occurs as early as 1 h after IRI. These
infiltrating T cells stay for at least 4 h, and vanish by 24 h.
These findings may explain why previous studies, including
our own, failed to identify T-cells infiltration as most studies
were performed at least 24 h after IRI. Early presence of T
cells after kidney IRI was reported previously in rats by de
Greef et al.27; however, those T cells were confined in the vasa
recta of the inner stripe of outer medulla. Our data support
the ‘hit-and-run’ hypothesis, showing that T-cell infiltration
is an early and transient event after renal IRI. This early T-cell
infiltration is associated with significant lymphocytopenia
(Figure 2b, lower panel), which has not been reported in the
literature. This association suggests that circulating T cells
participate in the inflammatory process of renal IRI.
Our finding of T-cell aggregates in the normal kidney is a
novel one. These T cells are specifically located in the
periarterial area between the renal cortex and the lining of
pelvic fornix. In the kidney, there are two major lymphatic
systems: a periarterial-hilar network and a subcapsular
network.28 The subcapsular network may participate in
draining the superficial cortex, whereas in the renal
parenchyma, the lymphatic capillaries typically drain along
the periarterial connective tissue until they form larger
channels in the renal hilus. Since the interlobar vessels,
including lymphatics, are located in the space between the
renal pelvis and the adjacent cortical parenchyma, the T-cell
aggregates we observed are likely to be associated with this
lymphatic system and may represent a reposing post for
traveling T cells. The observation of aggregates of unstimu-
lated T cells in normal kidney brings up an important issue
regarding the use of flow cytometry to quantify infiltrating T
cells in the total kidney. This method is likely to overestimate
the infiltrating T cells because the number obtained this way
may include non-infiltrating T cells.
The T cells in the periarterial lymphatic system may serve
as reserves, which can be mobilized rapidly in the event of
renal injury. In this study we provided two layers of support
for this hypothesis: (1) we have demonstrated that during
IRI, T cells in the lymphoid cell aggregates reduce
significantly and that this reduction is associated with the
increase of T-cell infiltration in renal interstitium; and (2)
S1P1-selective agonism significantly increases T cells in the
aggregates, while reducing IRI-induced T-cell infiltration.
These findings suggest that the lymphocyte aggregates play a
role in rapid T-cell infiltration after IRI. Whether similar
mechanism applies to other species deserves further inves-
tigation.
The mechanisms of T-cell infiltration during the early
phase of IRI are unknown. The rapid movement of T cells
suggests that it is mediated through an antigen-independent
activation.29 Our results support the notion that T cells are
activated and attracted by IRI-induced chemokines because
chemokine mRNA expression is stimulated several folds as
early as 1 h after reperfusion. More recently, Fiorina et al.14
have demonstrated that monokine-induced by interferon-g
(CXCL9) and interferon-inducible protein of 10 kDa
(CXCL10) were upregulated 6 h after reperfusion. They
found that CD3þ cells in the ischemic kidney of wild-type
mice were 2.4-fold of those in the CXCR3 knockout (KO)
mice. In addition, there was a preferential recruitment of Th2
cells in the CXCR3 KO mice. Their results indicate that
CXCR3 ligands play an important role in recruitment of Th1
cells to the ischemic kidney. Whether other Th1 preferential
chemokines, such as CCL2 and CCL5,10 are also critical for
T-cell recruitment remains to be determined. As for T-cell
clearance from ischemic kidney, the mechanisms are not
known. One potential mechanism is that T cells may be
repelled by the stromal cell-derived factor 1 (also known as
CXCL12), which is induced in the kidney by IRI30 and
capable of moving T cells away actively at high concentra-
tions.31 More importantly, if T cells come and are cleared so
quickly, what are the downstream mediators produced by
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Figure 6 | Pretreatment with SEW2871 (SEW) reduced acute
tubular necrosis scores at both 1 and 4 h of reperfusion. N¼ 4–6
per group. *Po0.05 vs IR only.
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levels after IRI. SEW2871 (SEW) treatment significantly reduced both
parameters at 4 and 24 h after reperfusion. N¼ 6. *Po0.05 vs IR.
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those T cells? Recently, Ascon et al.32 reported lymphocyte
trafficking into post-ischemic kidney. They demonstrated
that CD3þ T cells from ischemic kidney increased
production of tumor necrosis factor-a and interferon-g when
compared with normal- and sham-operated mice. These
results suggest that lymphocyte infiltrating into the post-
ischemic kidneys could have a major downstream effects on
subsequent inflammatory cascade and renal dysfunction.32
As for S1P1 expression, SEW2871 treatment did not have
any significant effects on S1P1 immunoreactivity in either
infiltrating T cells or T cells in the lymphocyte aggregate
(Figures 1b and 3a, lower panel, stained green). These results
are consistent with the previous reports showing that whereas
FTY720 causes internalization and degradation of S1P1
receptor, SEW2891 induces receptor internalization and
recycling, but not degradation.19 The S1P1 receptor plays
multiple roles in T-cell functions. At high concentrations
(0.3–3mM) comparable to the levels in the blood and lymph,
S1P inhibits chemotaxis and proliferation of T cells, and
cytokine production by activated T cells via the S1P1
receptor.33,34 However, most of the attention has been
focused on the role of the S1P–S1P1 signal transduction
pathway in T-cell trafficking. The S1P1 receptor in T cells is
essential for their egress from the secondary lymphoid organ.
S1P1-null T cells, when adoptively transferred into wild-type
mice, are sequestered in secondary lymphoid organs.23 But
the paradox is that S1P1 agonism has the same effect as S1P1
deletion in T cells, arguing against direct effects on T cells.
Recently, Wei et al.35 using real-time two-photon microscopy,
elegantly demonstrated that SEW2871 blocks lymphocyte
egress by inhibiting transendothelial migration, a finding that
supports the ‘stromal-gate control model’, which states that
the S1P1 agonists act on endothelial cells and close the gate by
tightening the junctions in the endothelium of lymphatic
sinuses.24 In our study, we demonstrated that SEW2871
blocks the T-cell egress from the renal lymphocyte aggregates.
These aggregates do not have the typical cortico–medullary
structure of lymph nodes; however, they are adjacent to
lymphatic vessels. SEW2871 causes T-cells log-jammed
against the endothelium in the aggregate (Figure 3a, lower
panel) similar to what have been reported in the secondary
lymph organ.18 Since these jammed CD4þ cells possess S1P1
receptor, our data suggest that the stromal-gate control
model may apply to the less structured T-cell aggregates in
the renal lymphatic system.
It is likely that the reduction of T-cell infiltration may
contribute to the renal protective effect of this S1P1 selective
agonist. Recently, Fiorina et al.14 have shown that CXCR3 KO
mice are protected against renal IRI and the renal protection
can be abrogated by adoptive transfer of wild-type CD3þ
cells. However, it should be mentioned that the role of T cells
in renal IRI has been controversial. There are studies that do
not support the T-cell theory. Recombination–activation
gene-1 knockout mice, which lack mature B and T cells, are
not protected from renal IRI.36 More recently, Faubel et al.37
reported that peripheral CD4þ T-cell depletion using CD4-
specific antibodies is not sufficient to prevent renal IRI. In
addition, T-cell receptor a-chain deficient (TCRa /) mice,
which lack the a-chain of the T-cell receptor and therefore
lack the functional CD4þ and CD8þ T cells, also develop
renal IRI. The different results from various mouse models
are not well understood. Frequently, KO mice develop
compensatory changes to overcome the functional deficiency
and may alter the response to IRI. For instance, the lack of
renal protection in the recombination–activation gene-1 KO
mice may be due to the enhanced innate immunity from the
upregulation of natural killer cells4 and the damage can be
ameliorated by adaptive transfer of either T or B cells.38
Further studies are needed to determine the role of T cells in
renal IRI. It is most likely that the S1P1 agonism induced
renal protection is multifaceted. In addition to its effects
on T cells, it may maintain endothelial integrity, reduce
vasoconstriction secondary to endothelial dysfunction, and
prevent further damage during the extension phase of
renal IRI.26,39,40
Conclusions and implications
We have demonstrated for the first time that after IRI, there is
an increase of T-cell infiltrates in the kidney as early as 1 h
and these infiltrating T cells vanish after 24 h, a phenomenon
consistent with the ‘hit-and-run’ theory. There are clusters of
T cells associated with the periarterial lymphatic network.
Both circulating T cells and T cells in renal lymphatic system
may be recruited to the kidney by T-cell chemokines after
IRI. S1P1 agonism ameliorates renal IRI and reduces T-cell
infiltration in the kidney probably by blocking T-cell egress
from both renal and remote lymphoid tissues. Our findings
suggest a critical role of S1P1 receptor in the pathophysiology
of renal IRI and may have important therapeutic implications
for the treatment of acute renal failure.
MATERIALS AND METHODS
Animals and procedures
Male NIH Swiss mice (20–25 g) were purchased from the National
Cancer Institute and allowed free access to water and standard
mouse chow. All procedures involving animals were approved by the
animal care committee of the University of Arizona and adhere to
the NIH Guide for the Care and Use of Laboratory Animals.
The renal ischemia and reperfusion procedure and SEW2871
treatment were performed as described previously.21 SEW2871 was
given at 20 mg/kg body weight via gavage 3 h before renal ischemia.
The mice in the IRI group alone received vehicle at the same time.
After anesthesia and abdominal incision, bilateral renal pedicles
were clamped using a nontraumatic microvascular clamp (Roboz
Surgical Instruments, Gaithersburg, MD, USA) for 30 min and then
released to allow reperfusion. Mice were killed at 1, 4, and 24 h after
ischemia and blood samples were collected for blood cell counts
with differentiation and for BUN and plasma creatinine levels,
performed by the Pathology Services at University of Arizona
Animal Care using the HEMAVET 850 Multispecies Hematology
Analyzer (Drew Scientific Inc., Oxford, CT, USA). The kidneys were
excised and processed for total RNA isolation, H & E staining for
histopathological scoring, and IF staining.
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Histopathology examination
Histological examinations were performed in a blinded fashion.
Histological changes due to tubular necrosis were semi-quantitated
as described previously with the following scoring system: 0¼ none,
1p10%; 2: 11–25%, 3¼ 26–45%, 4¼ 46–75%, and 5X76%.41 At
least 10 fields in the corticomedullary junction (original magnifica-
tion  400) were reviewed in each slide.
IF staining
The sources of the primary and secondary antibodies and counter-
stain are: rabbit anti-human S1P1 (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA) and rat anti-mouse CD4 (Biolegend, San
Diego, CA, USA); Alexa Flour 488 goat anti-rabbit IgG (Hþ L)
conjugate, Alexa Flour 594 rabbit anti-rat IgG (Hþ L) conjugate,
and far-red fluorescence nuclear counterstain TO-PRO-3 iodide
(Molecular Probes Inc., Eugene, OR, USA). IF staining was carried
out as described previously.21 Briefly, frozen kidney samples
embedded in 22-oxacalcitriol embedding medium (Tissue-Tek,
Sakura Finetechnical Co., Torrance, CA, USA) were cut into 5 mm
sections in a cryostat, fixed with 4% paraformaldehyde for 15 min,
and incubated with primary antibodies for 1 h, then with Alexa
Fluor-conjugated secondary antibodies for 30 min, all at room
temperature. Images were captured with a confocal laser-scanning
microscopy system (BioRad MRC-500) attached to a Nikon TMD-
300 microscope.
Quantitative Real-Time Reverse Transcription-Polymerase
Chain Reaction
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA), and first-strand cDNA was synthesized using the iScript
cDNA Synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA)
according to the manufacturer’s protocols. The mRNA abundance of
CCL2 (monocyte chemoattractant protein 1), CCL5 (RANTES), and
CXCL10 (interferon-inducible protein of 10 kDa) were assessed by
quantitative real-time reverse transcription-polymerase chain reac-
tion as described previously.42 Primer sequences are:
CCL2:
forward: 50-CAGCAAGATGATCCCAATGA-30,
reverse: 50-TCTGGACCCATTCCTTCTTG-30;
CCL5:
forward: 50-ATATGGCTCGGACACCACTC-30,
reverse: 50-TCCTTCGAGTGACAAACACG-30;
CXCL10:
forward: 50-GGTCTGAGTGGGACTCAAGG-30,
reverse: 50- GGTCTGAGTGGGACTCAAGG-30.
Statistical analysis
Non-normally distributed data were analyzed by the nonparametric
unpaired Mann–Whitney test. Multiple group comparisons were
performed using ANOVA with post-test according to Bonferroni.
o0.05 were considered statistically significant. Values are expressed
as means7s.e.
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